BAGSVAERD, DENMARK--(Marketwire - December 22, 2011) -
Novo Nordisk today announced the submission to the Japanese Pharmaceuticals
and Medical Devices Agency, PMDA, of a new drug application for the approval
of ultra-long-acting insulin Degludec. This new-generation basal insulin has
been developed for the treatment of people with type 1 and type 2 diabetes.
Company Announcemen no 80 / 2011:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE